Inside the unconventional FDA panel that could reshape the peptide industry

Peptides are under scrutiny in an FDA meeting running July 23-24 Olena Malik/Getty Images An unconventional FDA panel is reviewing peptide safety, focusing on banned therapeutic peptides. The FDA raised concerns over peptide safety, citing immune reactions and a lack of evidence of efficacy. Better access to peptides could open up a multibillion-dollar market for telehealth companies. Nearly 2 years after Robert F. Kennedy Jr. vowed to end the FDA's "war" on peptides, he has convened an…